SAVA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 11.72%, SMA50 7.94%, SMA200 -6.26%). The stock’s 14-day RSI is 57.73 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.81% below its high and over 104.35% above its low. Average 10-day trading volume of 547.17 thousand shares is below the 3-month average of 820.45 thousand, indicating normal recent market interest.

Cassava Sciences, Inc. generated EPS of -$2.20 over the past year. Five-year average earnings growth is -40.61%. The latest quarter delivered EPS of -$0.22. The next quarter is forecast at -$0.30. Next year's EPS is expected at $76.92. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $2.00. The high target offers 294.09% upside. The low target suggests -1.48% downside. The mean target is $5.00. This offers 146.31% upside. Cassava Sciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -17.12%. The prior quarter beat by -16.18%. Over the last six quarters, Apple has recorded several small beats. These include 25.0% in February 28, 2024.

Cassava Sciences, Inc. has 48.31 million shares outstanding. The public float is 43.48 million shares, elevated short interest at 13.05% of float. This equals 6.24 million shares. The short ratio is 7.24 days. Institutional investors hold 32.91% of the float. Insiders own 12.79%. Sabretooth Master Fund, L.P. holds 4.26 million shares, BARBIER REMI has 1.08 million shares and Barry Richard has 938.06 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Cassava Sciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.76. This means the shares are trading below this model’s fair value.

Cassava Sciences, Inc. (NASDAQ:SAVA) closed at $2.03 USD, losing -$0.01 (-0.49%) from the previous close of $2.04. The stock is currently mid-range between its 52-week high and low $1.15 and $4.98. With a market capitalization of about $98.07 million, Cassava Sciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.84). Key stats such as the average daily volume over the past year has been around 829.93 thousand shares, in line with its 52-week average. Headquartered in Austin, TX, Cassava Sciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard Jon Barry, the company employs approximately 30 people and listed since July 14, 2000. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.

Cassava Sciences, Inc. (NASDAQ:SAVA) shares are flat 0.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cassava Sciences, Inc. trading at a premium to the broader market with a P/E of -0.92. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $82.12, suggesting 3945.32% upside. Our AI forecast model points to short-term strength (6.9% over two weeks), a medium-term rise (101.97% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cassava Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.9%, with price expected at $2.17 by March 20, 2026, within a range of $2.07 to $2.27 3-Month Outlook: Projected rise of 101.97%, reaching $4.10 by June 04, 2026, with a range of $3.31 to $4.80. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by March 05, 2027, within a range of $0.00 to $1.19.

Cassava Sciences, Inc. trades at a P/E ratio of -0.92, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.2 suggesting the stock is closer to book value. The P/FCF stands at -1.17, also below market averages.